All news

Wells Fargo names Annexon top biotech pick

Alpha Vantage · Investing.com · · AI-summarised by FinFlash

Wells Fargo reiterated an Overweight rating and $27.00 price target on Annexon (ANNX), calling it its top pick in biotechnology. The firm cites the fourth-quarter 2026 ARCHER II data readout in generalized myasthenia gravis, assigning a 55% probability of a positive Month-15 outcome, plus a financial runway into 2028.

Read original source

WFC company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.